Agenus(NASDAQ) AGEN

Market Cap$394.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)-100%
5 Year-92%
1 Year+111%
1 Month+6%
Premium Feature
Moneyball Superscore
41/100
$7.89
-9.62%
-0.84Today
Agenus last closing stock price
MetricPriceDate
Last closeUSD 8.732026-10-05
Agenus stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.42%USD 9.432026-09-28
1 month+5.95%USD 8.242026-09-04
3 month+149.43%USD 3.502026-07-07
Year to date+178.03%USD 3.142025-12-31
1 year+110.87%USD 4.142025-10-03
3 year-58.82%USD 21.202023-10-06
5 year-92.11%USD 110.692021-10-06
Since inception-99.88%USD 7,227.312000-02-04

Agenus Financials at a Glance

Market Cap

$394.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$132.69

Net Income (TTM)

$91.94

EPS (TTM)

$2.65

P/E Ratio

3.29

Dividend

$0.00

Beta (Volatility)

1.81 (High)

Price

$7.89

Volume

698,003.816

Open

$8.49

Previous Close

$8.73

Daily Range

$7.90 - $8.49

52-Week Range

$2.71 - $10.31

Estimated Earnings Date

N/A

AGEN: Motley Fool Moneyball Superscore

41

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Agenus

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Industry

Biotechnology

Employees

81

CEO

Garo H. Armen, PhD

AGEN Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

30.40%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$394.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

45.16M

Volume

698.00K

Avg. Volume

4.19M

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Agenus Performance Analysis

Agenus annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 98,024,000-66.8%
20232023-12-31USD 156,314,00059.5%
20242024-12-31USD 103,463,000-33.8%
20252025-12-31USD 114,196,00010.4%
Agenus annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -15.64641.5%
20232023-12-31USD -13.75-12.1%
20242024-12-31USD -10.59-22.9%
20252025-12-31USD -0.00-100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$34.52

+1.3%

Gross Profit

$34.00

+1.5%

Gross Margin

98.50%

+1.1%

Market Cap

$394.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.57

N/A

Employees

81

N/A

Net Income

-$0.57

+0.0%

EBITDA

$11.81

-0.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$308.91

-25.1%

Total Debt

$290.17

+0.7%

Accounts Receivable

$47.59

+67.1%

Inventory

$0.00

N/A

Long Term Debt

$145.33

+0.5%

Short Term Debt

$144.84

+1.2%

Return on Assets

51.42%

-0.7%

Return on Invested Capital

136.28%

+2.0%

Free Cash Flow

-$31.20

+1.5%

Operating Cash Flow

-$31.20

+1.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,777.74+0.01%
^DJIDJI
$51,304.21+0.00%
^IXICNASDAQ
$27,461.27+0.01%
BTCBitcoin
$85,510.00+0.00%

Questions About AGEN

What is the current price of Agenus?

Agenus is trading at $7.91 per share.

What is the 52-week range for Agenus?

Over the past 52 weeks, Agenus has traded between $2.71 and $10.31.

How much debt does Agenus have?

As of the most recent reporting period, Agenus reported total debt of $290.17M.

How much cash does Agenus have on hand?

Agenus reported $18.74M in cash and cash equivalents in its most recent financial results.

What is Agenus’s dividend yield?

Agenus does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.